Dr. Monga is the SVC Endowed Chair in Pathobiology and Therapeutics and Professor of Pharmacology and Medicine at the University of Pittsburgh. He is the Chair/Director of the Organ Pathobiology and Therapeutics Institute. He is also the director of the Pittsburgh Liver Research Center, an NIDDK P30 funded Digestive Disease Research Core Center and the program director of the NIBIB-funded predoctoral training program entitled Cellular Approaches to Tissue Engineering and Regeneration. He serves as the Associate Dean of Research for the University of Pittsburgh School of Medicine.

I am currently Professor and Vice Chair for Research of the Department of Anesthesiology, McGovern Medical School, University of Texas Health Science Center at Houston (UTHealth). I received my PhD in drug metabolism and toxicology from the University of Toronto, Canada in 1999, followed by postdoctoral training at the National Heart Lung and Blood Institute (NHLBI). I joined the School of Pharmacy, University of Colorado as an Assistant Professor in 2002, and was promote to Associate and Full Professor in 2009 and 2015, respectively.

I am currently a member of the Department of Pharmacology and Toxicology at Michigan State University. My research has focused on the role of hypoxia and hypoxia-inducible factors in liver fibrosis and also on the immunoregulatory properties of bile acids during cholestatic liver disease. More recently my work has focused on elucidating the mechanisms that drive the transition from severe acute liver injury to acute liver failure.

Dr. Carmen Chak-Lui Wong is currently a Professor and Principal Investigator in the Department of Pathology and State Key Laboratory of Liver Research at the University of Hong Kong (HKU). She is currently the Assistant Dean of the LKS Faculty of Medicine at HKU. She is the program leader of the liver cancer program at Center of Oncology and Immunology at InnoHealth, Hong Kong.

Dr McLin is the Medical Director of the Swiss Pediatric Liver Center, and the Head of the Unit of Gastroenterology, Hepatology, and Nutrition at University Hospitals Geneva in Switzerland. She is the Principal Investigator of the International Registry of Congenital Portosystemic Shunts (www.ircpss.com).

Dr. Gilmour is a graduate of the University of Saskatchewan and pursued post-graduate training at The Hospital for Sick Children, Toronto.

I am a pediatric surgeon trained in transplantationand have directed the liver transplant program at the Ann & Robert H. Lurie Children's Hospital since its inception. I have a special interest in disorders of the liver in children including abnormalities of portal circulation, biliary atresia and pediatric liver tumors.

I am a board certified pediatric gastroenterologist and transplant hepatologist, and current an Assistant Professor at the University of Chicago in the section of Pediatric Gastroenterology, Hepatology, and Nutrition. My clinical interests include MASLD and obesity, autoimmune liver diseases, cystic fibrosis associated liver disease, and biliary atresia. My research interests include understanding and addressing psychosocial aspects of hepatology and pediatric liver transplantation.

Janis Stoll, M.D., is the Medical Director of the Pediatric Liver Transplant program and the Healthy Start Clinic at St. Louis Children's Hospital and Washington University School of Medicine. Under her leadership since 2020, the transplant program continues to expand while advancing clinical capabilities to include living donation, combined heart-liver transplantation, and ABO-incompatible liver transplantation for a complex patient population of over 170 transplant patients. Passionate about quality improvement, Dr.

Dr. Sumera I. Ilyas is an Associate Professor of Medicine at Mayo Clinic in Rochester MN. She is a physician-scientist with an academic focus in hepatobiliary neoplasia. She is the director of the Mayo Clinic Hepatobiliary Neoplasia Clinic and Transplant Oncology Clinic. She has a discovery science program focused on the immunobiology of cholangiocarcinoma and development of combination immune-directed therapies for the treatment of cholangiocarcinoma.